Docket No. PRD0036NP



Applicants: Hui Cai et al.

Serial No.: 10/656,059

Art Unit:

Filed

: September 5, 2003

Examiner:

For

: HETEROCYCLIC COMPOUNDS

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner For Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on

December 4, 2003
(Date of Deposit)

(Date of Deposit)

John W. Harbour

(Name of applicant, assignee, or Registered Representative)

December 4, 2003

(Date of Signature)

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Dear Sir:

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §§1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. §1.56(b).

Applicant(s) reserve(s) the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist.

igtimes In accordance with §1.97(b), since this Information
Disclosure Statement is being filed either within three months
of the filing date of the above-identified national application
(other than a continued prosecution application under
§1.53(d)), within three months of the date of entry into the
national stage of the above identified application as set forth
in §1.491, or before the mailing date of a first Office Action
on the merits of the above-identified application, or before
the mailing date of a first Office Action after the filing of a
request for continued examination under §1.114, no additional
fee is required.
In accordance with §1.129(a), this Information
Disclosure Statement is being filed in connection with the
first or Second After Final Submission, therefore:
<pre>Statement in Accordance with §1.97(e)</pre>
(attached); or
Please charge Deposit Account No. 10-
0750/ / the fee of $$180.00$ as set forth
in §1.17(p).
☐ In accordance with §1.97(c), this Information
Disclosure Statement is being filed after the period set forth
in §1.97(b) above but before the mailing date of either a Final
Action under §1.113 or a Notice of Allowance under §1.311, or
an action that otherwise closes prosecution and that it is
accompanied by one of:
<pre>Statement in Accordance with §1.97(e)</pre>
(attached); or

Please charge Deposit Account No. 10-
0750/ / the fee of $$180.00$ as set forth
in §1.17(p).
In accordance with §1.97(d), this Information
Disclosure Statement is being filed after the mailing date of
either a Final Action under §1.113 or a Notice of Allowance
under §1.311 but before the payment of the Issue Fee.
Applicant(s) hereby petition(s) for consideration of this
Information Disclosure Statement. Included are: Statement in
Accordance with §1.97(e) as set forth below and the fee of
\$180.00 as set forth in §1.17(p).
igtiim Copies of each of the references listed on the
attached Form PTO-1449 are enclosed herewith.
Copies of references listed on the attached Form PTO-
1449 are enclosed herewith EXCEPT THAT:
In view of the voluminous nature of references
[list as appropriate], and the likelihood that
these references are available to the Examiner,
copies are not enclosed herewith.
If any of the foregoing publications are not
available to the Examiner, Applicant will
endeavor to supply copies at the Examiner's
request.
Copies of only foreign patent documents and non-
patent literature are enclosed in accordance with 37 CFR 1.98
(a)(2). (The U.S. patents and each U.S. patent application
publication listed on the attached Form PTO-1449 are not
enclosed because this U.S. patent application was filed after
June 30, 2003 or this international application has entered the

. .

. .

national stage under 35 USC §371 after June 30, 2003 (see USPTO waiver of requirement under 37 CFR 1.98 (a)(2)(i).

There are no listed references which are not in the English language.

The relevance of those listed references which are not in the English language is as follows:

Attached are copies of search report(s) from corresponding patent application(s), which are listed on the attached Submission Under MPEP 609 D.

Attached are the following non-published pending patent applications which may be deemed relevant, which are listed on the attached Submission Under MPEP 609 D.

Please charge any deficiency or credit any overpayment to Deposit Account No. 10-0750/PRD0036/JWH. This form is submitted in triplicate.

Respectfully submitted,

John W. Harbour

Reg. No. 31,365

Attorney for Applicants

Johnson & Johnson One Johnson & Johnson Plaza New Brunswick, NJ 08933-7003 (732) 524-2169 DATED: December 4, 2003 JC 81 337

PTO/SB/08A (08-00) Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

Succentute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)
Sheet 1 of 2

collection of information unless it displays a valid OMB control number.				
Application Number	10/656,059			
Filing Date	September 5, 2003			
First Named Inventor	Hui Cai			
Group Art Unit				
Examiner Name				
Attorney Docket Number	PRD0036NP			

U.S. PATENT DOCUMENTS						
U.S. Patent Document			ocument		Date of Publication	Pages, Columns, Lines,
Examiner Initials	Cite No.1	Number	Kind Code ² (if known)	Name of Patentee or Applicant of Cited Document	of Cited Document mm-dd-yyyy	where relevant passages or relevant figures appear
ATT ==				· -	_	
					_	
·				48		
	57 1					

FOREIGN PATENT DOCUMENTS Pages, Columns, Lines, Foreign Patent Document Date of Publication of Cited Document where relevant Name of Patentee or passages or relevant Cite Examiner mm-dd-yyyy Applicant of Cited Document figures appear Initials Office³ Number⁴ KindCode⁵ No.1 wo 9940914 Zeneca Limited 08-19-1999 ΕP Pfizer Products Inc. 06-27-2001 1088824 Α3 ΕP 1136071 A2 Pfizer Products Inc. 09-26-2001

Examiner Date	
Signature Considered Considered	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS, SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. 2 See attached Kinds of U.S. Patent Documents. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3), 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 144

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE to a collection of information unless it displays a valid OMB control number.

work Reduction Act of 1995, no persons are required to respond to

ORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary) Sheet 2 of 2

a collection of information utiless it displays a valid OMB control number.				
Application Number	10/656,059			
Filing Date	September 5, 2003			
First Named Inventor	Hui Cai			
Group Art Unit				
Examiner Name				
Attorney Docket Number	PRD0036NP			
	1			

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item	
Examiner's	Cite	(book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s),	T ²
nitials*	No.1	publisher, city and/or country where published	
		DETTY M.R. et al. Studies Toward Alkylthiophene-2-Carboxaldehydes. Reduction of 3-Alkenylthiophenes with	
		Triethylsilane/Trifluoroacetic Acid. Regioselectivity in Formylation Reactions of 3-Alkylthiophenes. Heterocycles (1995) 40(2):925-937	
		KONDO, K. et al. Synthetic Utility of tert-Butyl Azidoacetate on the Hemetsberger-Knittel Reaction (Synthetic Studies of Indoles and Related Compounds Part 47). Chem. Pharm. Bull. (1999) 47(9):1227-1231	
		IRIARTE, J. et al. The Chlorination of Thiophene-2-aldehyde and Ethyl Thiophene-2-carboxylate in the Presence of Excess Aluminum Chloride. J. Het. Chem. (1976) 13:393-394.	
		ARRANG, JM. et al. Auto-inhibition of Brain Histamine Release Mediated by a Novel Class (H3) of Histamine Receptor. Nature (1983) 302:832-837	
		ASH, A.S.F.; SCHILD, H.O. Receptors Mediating Some Actions of Histamine. Br. J. Pharmac. Chemother. (1966) 27:427-439	
		BARGER, G.; DALE, H.H. Chemical Structure and Sympathomimetic Action of Amines. J. Physiol. (1910) 41:19-59 Reprinted in Adventures in Physiology; Sir Henry H. Dale, Ed.; The Wellcome Trust: London, 1965; pp 67-98.	
		BLACK, J.W. et al. Definition and Antagonism of Histamine H2-Receptors. Nature (1972) 236:385-390	
		GANTZ, I. et al. Molecular Cloning of a Gene Encoding the Histamine H2 Receptor. Proc. Natl. Acad. Sci. USA (1991) 88:429-433	
		HILL, S.J. et al. International Union of Pharmacology. XIII. Classification of Histamine Receptors. Pharmacol. Rev. (1997) 49(3):253-278	
		LIU, C. et al. Cloning and Pharmacological Characterization of a Fourth Histamine Receptor (H4) Expressed in Bone Marrow. Mol. Pharmacol. (2001) 59(3):420-426	
		LOVENBERG, T.W. et al. Cloning and Functional Expression of the Human Histamine H3 Receptor. Mol. Pharmacol. (1999) 55(6):1101-1107	
		MORSE, K.L. et al. Cloning and Characterization of a Novel Human Histamine Receptor. J. Pharmacol. Exp. Ther. (2001) 296(3):1058-1066	
		NGUYEN, T. et al. Discovery of a Novel Member of the Histamine Receptor Family. Mol. Pharmacol. (2001) 59(3):427-433	
		ODA, T. et al. Molecular Cloning and Characterization of a Novel Type of Histamine Receptor Preferentially Expressed in Leukocytes. J. Biol. Chem. (2000) 275(47):36781-36786	
		RAIBLE, D.G. et al. Pharmacologic Characterization of a Novel Histamine Receptor on Human Eosinophils. Am. J. Respir. Crit. Care Med. (1994) 149:1506-1511	
		YAMASHITA, M. et al. Expression Cloning of a cDNA Encoding the Bovine Histamine H1 Receptor. Proc. Natl. Acad. Sci. USA (1991) 88:11515-11519	
		ZHU, Y. et al. Cloning, Expression, and Pharmacological Characterization of a Novel Human Histamine Receptor. Mol. Pharmacol. (2001) 59(3):434-441	
	-		
	_		

Examiner	Date	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA

22313-1450.

¹ Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.